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Abstract
Background: miR-23b is located on chromosome number 9 and plays different roles in different organs especially with
regards to cancer development. However, the functional significance of miR-23b-3p in renal cell carcinoma (RCC) has not
been reported.
Methods and Results: We measured miR-23b-3p levels in 29 pairs of renal cell carcinoma and their normal matched tissues
using real-time PCR. The expression level of miR-23b-3p was correlated with the 5 year survival rate of renal cancer patients.
In 15 cases (52%), miR-23b-3p expression was found to be high. All patients with moderate to low miR-23b-3p expression
survived 5 years, while those with high miR-23b-3p expression, only 50% survived. After knocking down miRNA-23b-3p
expression in RCC cell lines, there was an induction of apoptosis and reduced invasive capabilities. MiR-23b-3p was shown
to directly target PTEN gene through 39UTR reporter assays. Inhibition of miR-23b-3p induces PTEN gene expression with
a concomitant reduction in PI3-kinase, total Akt and IL-32. Immunohistochemistry showed the lack of PTEN protein
expression in cancerous regions of tissue samples where the expression of miR-23b-3p was high. We studied the in vitro
effects of the dietary chemo preventive agent genistein on miR-23b-3p expression and found that it inhibited expression of
miR-23b-3p in RCC cell lines.
Conclusions: The current study shows that miR-23b-3p is an oncogenic miRNA and inhibits PTEN tumor suppressor gene in
RCC. Therefore, inhibition of miR-23b-3p may be a useful therapeutic target for the treatment of renal cell carcinoma.
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Introduction
miRNAs have been shown to be involved in various kidney
diseases [1]. miR-23b is located on chromosome number 9 in
a cluster with miR-27b and miR-24-1 [2]. It has been shown to
play different roles in different organs especially with regards to
cancer development. In cancers like bladder and oral squamous
cell carcinoma [3–4] it has been shown to be over expressed. In
renal cancer miR-23b-5p acts as a potential oncomir by
suppressing proline oxidase, which is a novel tumor suppressor
protein [5]. Whereas in prostate cancer [6], it plays the role of
a tumor suppressor microRNA as it is targeted by the
oncogenic transcription factor c-myc. This eventually results in
an increase in the protein expression of the pro-cancerous
enzyme mitochondrial glutaminase, which is a target for miR-
23b [7]. In breast cancer it has been shown to be up regulated
with miR-27b and miR-24-1 by the oncosuppressor transcrip-
tion factor ERb [8]. Similarly, in hepatocellular carcinoma it
acts as a tumor suppressor by targeting the Urokinase-type
plasminogen activator (uPA) and c-met resulting in decreased
migration and proliferation of HCC cells [9]. In colon cancer it
functions in suppressing cancer metastasis by targeting prometa-
static genes FZD7 or MAP3k1 [10].
In this study, we examined the role of miR-23b-3p in renal clear
cell carcinoma. We found that expression of miR-23b-3p was
increased in A-498 and Caki-2 cell lines and a majority of tissue
samples. Increased expression also correlated with lower survival
rate for renal cell carcinoma patients. Inhibition of miR-23b-3p
expression in A-498 and Caki-2 cells caused an increase in
apoptosis and a decrease in invasive properties. PTEN protein
expression was found to be increased after knocking down miR-
23b-3p in A-498 cells with a concomitant decrease in the
expression of PI3-kinase, total Akt and IL-32. The PTEN gene
was shown to be a direct target of miR-23b-3p by 39 luciferase
reporter assays. Immunohistochemistry showed the lack of PTEN
protein expression in cancerous regions of tissue samples where the
expression of miR-23b-3p was high.
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Results
miR-23b-3p is Up Regulated in Renal Carcinoma Tissue
Samples and Renal Cancer Cell Lines
To understand the clinical relevance of miR-23b in kidney
cancer we measured miR-23b-3p levels in 29 pairs of human
kidney cancers (all clear cell renal cell carcinoma) and matched
normal tissues by real-time PCR. In 15 cases (52%), miR-23b-
3p was found to be increased (T/N [Tumor/Normal] was
greater than 1.2). In 5 samples (17%) the expression was
moderate (T/N 0.8–1.2). Expression of miR-23b-3p was also
measured in cultured renal cancer cell lines, A-498, ACHN,
Caki-1, Caki-2 and non malignant normal HK-2 cells. miR-
23b-3p expression in A-498 cells was approximately 11x that of
HK-2 cells while that of ACHN was 4.1x, Caki-1 4.8x, and
Caki-2 5.8x (Figure 1).
Correlation of miR-23b-3p Expression with Survival in
Renal Cancer
The expression level of miR-23b-3p correlated with 5 year
survival of the patients. For those patients with moderate to low
miR-23b-3p expression (n= 12) (Figure 2), all survived 5 years
after surgery, while those with high miR-23b-3p (n = 12)
expression, only 50% survived (Figure 2). The survival curve was
based on the number of patients (24) for which we had survival
information out of a total of 29 patients. No correlation between
tumor grade, stage and miRNA-23b-3p levels were observed.
Functional Role of miR-23b-3p in A-498 Cells
To elucidate the functional role of miR-23b-3p in renal cancer
we knocked down the expression of miR-23b-3p in A-498 and
Caki-2 renal cancer cells with a commercially available miR-23b-
3p inhibitor. Anti-miR-Negative control #1 was also used for
these experiments. The miR-23b-3p level was reduced by more
than 99%, as compared to the negative control in A-498 cells
Figure 1. qRT-PCR expression of miR-23b-3p in renal cancer tissues and cell lines. A) Ratio of T/N expression in tissue samples was found
to be high in a majority of samples. B) A-498 and Caki-2 cells had high expression of miR-23b-3p as compared to non malignant normal HK-2 cells (T-
Tumor,N-Normal), [p value (A) 0.032; p value (B) 0.018)].
doi:10.1371/journal.pone.0050203.g001
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(Figure 3a). Anti-miR-23b-3p transfection into Caki-2 cells also
reduced the level of miR-23b-3p expression in these cells
(Figure 3b).
Effect on Cell Cycle and Apoptosis
The effects of miR-23b-3p knock down on the cell cycle and
apoptosis were analyzed by flow cytometry. Apoptosis assay
showed a significant increase in the number of total apoptotic cells
(early apoptotic plus apoptotic) in both A-498 (8.87%) (Figure 4a)
and Caki-2 cells (11.74%) (Figure 4b) with miR-23b-3p knock
down as compared to the negative control [A-498 (3.37%) and
Caki-2 (3.68%)]. There were no significant changes in the cell
cycle for both A-498 and Caki-2 cells (data not shown).
Effect on Cell Invasion and Migration Properties
To determine whether miR-23b-3p affects renal cancer cell
migration and invasion a cytoselect 24-well cell migration and
invasion kit was used. A-498 and Caki-2 cells were transfected with
anti-miR-23b-3p inhibitor and anti-miR-Negative control. Both
A-498 and Caki-2 cells showed a 30% decrease in cell invasion in
the samples where miR-23b-3p was inhibited as compared to
negative controls (Figure 5a and 5b). No significant change in
migration was observed in both A-498 and Caki-2 cells (data not
shown).
PTEN is Increased After Knock Down of miR-23b-3p in A-
498 Cells
To see the effect of miR-23b-3p expression on different genes
involved in apoptosis and invasion we checked the protein
expression of several genes involved in these processes. The pro
apoptotic gene PTEN was found to be up regulated after miR-
23b-3p knock down in A-498 cells (Figure 6A). We also found
a decrease in the protein levels of PI3-kinase and total Akt.
Interestingly, a decrease in the expression of the pro inflammatory
cytokine IL32 was also observed after miR-23b-3p knock down.
The protein expression levels were quantified by optical
densitometry using ImageJ Software version 1.36b (http://rsb.
info.nih.gov/ij/). Fold change was calculated as the ratio between
the net intensity of each sample transfected with anti-miR-23b-3p
divided by GAPDH and the negative control transfected samples
divided by the GAPDH (Anti-miR-23b-3p transfected samples/
Figure 2. Correlation of miR-23b-3p expression with 5 year survival of renal cell carcinoma patients (p value 0.017).
doi:10.1371/journal.pone.0050203.g002
Figure 3. Expression of miR-23b-3p after knock down. Expression of miR-23b-3p was decreased by more than 99% after its inhibition in both
A-498 (A) and Caki-2 cells (B).
doi:10.1371/journal.pone.0050203.g003
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GAPDH)/(Neg Control miR transfected samples/GAPDH)
(Figure 6B).
PTEN is a Direct Target of miR-23b-3p
Since a significant increase in apoptosis was observed in both A-
498 and Caki-2 cells and increased PTEN expression in A-498
cells after miR-23b-3p knock down, we looked to see if miR-23b-
3p targets the pro apoptotic gene PTEN. Using TargetScan
(targetscan.org) and microrna.org we identified complementary
sequences to miR-23b in the 39UTR of the PTEN gene (Figure 7a).
We carried out luciferase reporter assays using a 39PTEN
construct with miR-23b-3p or miR-Control- expressing A-498
cells and observed a consistent reduction of luciferase activity
(Figure 7b) in miR-23b-3p transfectants suggesting that miR-23b-
3p represses PTEN directly.
Expression of PTEN Protein in Normal and Cancer
Regions of Tissue Samples having a High Expression of
miR-23b-3p
To further confirm that PTEN is a target of miR-23b-3p we
checked for expression of PTEN protein in normal and cancer
regions of patient tissue samples which had a high expression of
miR-23b-3p, using immunohistochemistry (IHC). Ten samples
having high miR-23b-3p expression were selected. A representa-
tive example of PTEN immunohistochemistry is shown in
Figure 8A.
IHC staining results for tissues were graded according to quick
score (percent cells stained 6 intensity of stain). Quick score
obtained from the tumor samples was normalized with the quick
score of their normal samples (T/N) and Chi-square test was
performed with the miR-23b-3p expression levels in the same
patient samples (Figure 8B). All normal samples expressed PTEN
protein though at varied levels. PTEN staining was absent from
the tumor samples that expressed higher levels of miR-23b-3p
(p,0.001) (Figure 8B).
Genistein Decreases the Expression of miR-23b-3p in A-
498 Cells
We also examined the effect of the chemoprevention agent,
genistein (a soy product), on the expression of miR-23b-3p in A-
498 cells. Treatment with genistein (25 mM) for 96 hours
decreased the expression of miR-23b-3p by 50%, whereas a higher
concentration of genistein (50 mM) for the same period of time
decreased expression by 45% (Figure 9).
Discussion
The present study shows that miR-23b-3p functions as an
oncogenic microRNA in renal cell carcinoma. Its expression is
increased in renal cell carcinoma cell lines and tissue samples (clear
cell carcinoma) as compared to normal renal cells and matched
normal tissues, respectively. In addition we found that high levels
of miR-23b-3p lead to lower survival for renal cancer patients. To
study the functional role of miR-23b-3p its expression was knocked
down in A-498 and Caki-2 renal cancer cell lines. This led to an
increase in the total number of cells undergoing apoptosis in both
cell lines compared to controls. However, there was no significant
change in the cell cycle. In addition A-498 and Caki-2 cells showed
decreased cell invasion in miR-23b-3p knocked down cells but no
significant change in migration. Western analysis of miR-23b-3p
knock down showed increased PTEN expression and concomitant
decreases in the expression of PI3-kinase, Akt and IL-32. PTEN
was found to be a direct target of miR-23b-3p through reporter
gene assays.
The significant change in the number of apoptotic cells after
knock down of miR-23b-3p in both A-498 and Caki-2 cells lead us
to search for genes and pathways involved in apoptosis. Previous
studies have shown that PTEN can induce apoptosis through
a PI3-kinase dependent pathway [11]. PTEN acts as a tumor
suppressor gene through the action of its phosphatase protein
product [12], degrading PIP3 to inactive phosphatidylinositol
(4,5)-diphosphate PIP2 [13,14]. This in turn negatively regulates
the pro-survival PI3K/Akt signaling pathway. The phosphatidy-
linositol 3-kinase (PI3K) pathway regulates various cellular pro-
cesses, including proliferation, growth, apoptosis and cytoskeletal
Figure 4. Effect on apoptosis after miR-23b-3p knock down in A-498 and Caki-2cells. A) Apoptosis assay showed a significant increase in
the number of total apoptotic cells (8.87%) in the anti- miR-23b-3p inhibitor transfected cells as compared to the negative control (3.37%) in A-498
cells (p value 0.029). B) In Caki-2 cells the total number of apoptotic cells (11.74%) in the anti- miR-23b-3p inhibitor transfected cells as compared to
the negative control (3.68%) (p value 0.030).
doi:10.1371/journal.pone.0050203.g004
Figure 5. Effect of miR-23b-3p knock down on cell invasion in A-498 and Caki-2 cells. Invasive properties of A-498 (A) and Caki-2 (B) cells
were decreased by 30% after miR-23b-3p knock down compared to controls. Y-axis-Absorbance at 560 nm [p value(A) 0.026; p value(B) 0.030].
doi:10.1371/journal.pone.0050203.g005
miRNA-23b-3p in Renal Cell Carcinoma
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rearrangement. PI3Ks are heterodimeric lipid kinases that are
composed of regulatory and catalytic subunits encoded by different
genes [15]. One of the main functions of PI3K is to synthesize the
second messenger PtdIns(3,4,5)P3 (PIP3) from PtdIns(4,5)P2
(PIP2). AKT, a serine/threonine kinase that has a wide range of
substrates, is activated by recruitment to the plasma membrane
Figure 6. Western analysis of apoptosis and invasion genes after knock down of miR-23b-3p in A-498 cells. A) Expression of PTEN, PI3-
kinase, Akt and IL-32 in A-498 cells, compared to negative control. GAPDH was used as a normalizing control. B) Quantitative data for Western blot
analysis. PTEN was up regulated, whereas PI3-kinase, Akt and IL-32 expression were down regulated.
doi:10.1371/journal.pone.0050203.g006
Figure 7. PTEN is a direct target of miR-23b-3p. A) Software analysis shows sequences complementary to the seed sequences of miR-23b-3p in
the 39 UTR of PTEN gene. B) Luciferase assay showed a decrease in relative luciferase units in samples co transfected with miR-23b-3p was and PTEN
39 UTR gene construct as compared to control constructs (Neg Con-negative control; Con-Control plasmid construct lacking PTEN 39UTR sites for miR-
23b-3p; PTEN-PTEN plasmid construct having PTEN gene 39UTR sites for miR-23b-3p; (p value 0.017).
doi:10.1371/journal.pone.0050203.g007
miRNA-23b-3p in Renal Cell Carcinoma
PLOS ONE | www.plosone.org 6 November 2012 | Volume 7 | Issue 11 | e50203
through direct contact of its pleckstrin-homology (PH) domain
with PIP3, and phosphorylation at Thr308 and Ser473. AKT acts
downstream of PI3K to regulate many biological processes, such
as proliferation, apoptosis and growth, but other signaling
pathways are also known to be regulated by PI3K activity and
might be involved in PI3K-mediated tumorigenesis. PTEN is one
of the most commonly lost tumor suppressor genes in human
cancer. During tumor development, mutations and deletions of
PTEN occur that inactivate its enzymatic activity leading to
increased cell proliferation and reduced cell death. Frequent
genetic inactivation of PTEN occurs in glioblastoma, endometrial
cancer, prostate cancers; and reduced expression is found in many
other tumors such as lung and breast cancer [15]. In this study
Western analysis also showed a decrease in IL-32 expression after
the inhibition of miR-23b-3p in A-498 cells. We did not monitor
IL-32 in the culture media. IL-32 is a cytokine and it’s pro-
cancerous role has been documented in several studies [16,17,18].
The PI3-kinase pathway has been shown to induce IL-32
expression in a number of studies [19,20,21,22], especially in
pancreatic cancer where its pro- cancerous role has been
established. Therefore, these studies suggest that the reason for
the decreased IL-32 expression upon knock down of miR-23b-3p
is that it also affects the expression of PI3-kinase and Akt. A
software search for miR-23b-3p binding sites on PI3-kinase and
Akt was carried on however we did not find any evidence that PI3-
kinase and Akt are direct targets of miR-23b-3p.
Genistein (40,5,7-trihydroxyflavone), one of the principal soy
isoflavones, has a wide array of chemopreventive actions. The
anticancer effects of genistein have been ascribed to several
signaling pathways and mechanisms that affect cell cycle arrest,
apoptosis, invasion, metastasis and angiogenesis, attributes that
could potentially prevent tumor initiation and progression [23,24].
Figure 8. Expression of PTEN protein in normal and cancer regions of tissue samples having high expression of miR-23b-3p. A)
Representative pictures of Immunohistochemistry (IHC) analyses. B) Graphical representation of the data showing that PTEN expression was high in
normal regions of renal cancer patient samples whereas in cancerous regions having high miR-23b-3p expression PTEN was not observed.
doi:10.1371/journal.pone.0050203.g008
Figure 9. In vitro effect of genistein on the expression of miR-
23b-3p. miR-23b-3p expression was reduced by 50% in 25 mM
genistein treated A-498 cells as compared to untreated cells, 50 mM
genistein decreased miR-23b-3p expression by 45% (p value 0.030).
doi:10.1371/journal.pone.0050203.g009
miRNA-23b-3p in Renal Cell Carcinoma
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Genistein is abundant in soy products and has been identified as
an inhibitor of protein tyrosine kinases and thus may play a key
role in cell growth and apoptosis [25,26]. It has been reported to
have estrogenic properties and anti-neoplastic activity in multiple
tumor types [27]. In a previous study Hillman et. al. have shown
that the combination of genistein with primary tumor irradiation
acts effectively as a therapeutic approach, in established kidney
tumors, due to tumor growth being inhibited at both the primary
and metastatic sites. In their study genistein alone had a tendency
to stimulate growth of primary kidney tumor and increase
metastasis [28]. Thus these findings prompted us to monitor the
expression of miRNA-23b-3p after treatment of A-498 cells with
different concentrations of genistein. We found a 50% decrease in
the expression of miR-23b-3p after treatment of A-498 cells with
25 mM genistein for 96 hours (Figure 8). In a previous study [29]
we also reported a decrease of miR-21 expression in mouse
xenograft tumors formed after injecting 25 mM genistein treated
A-498 cells subcutaneously in nude mice as compared to smaller
tumors formed by untreated A-498 cells. We also measured the
expression of miR-23b-3p in those tumors and could not find any
significant change in its expression.
In summary, miR-23b-3p is an oncogene in RCC and directly
inhibits the PTEN tumor suppressor gene. Thus miR-23b-3p may
be useful as a renal cancer diagnostic marker and as a therapeutic
target for the treatment of renal cell carcinoma.
Materials and Methods
Ethics Statement
Formalin-fixed, paraffin-embedded (FFPE) renal cancer samples
were obtained from the San Francisco Veterans Affairs (VA)
Medical Center. Written informed consent was obtained from all
patients and the study was approved by the UCSF Committee on
Human Research (Approval number: H9058-35751-01).
Cell Lines and Cell Culture
Human renal cancer cell lines A-498, ACHN, Caki-1, Caki-2,
and a normal renal cell line (HK-2) were obtained from the
American Type Culture Collection (ATCC, Manassas, VA, USA).
Integrity of the cell lines was confirmed by the ATCC using DNA
(STR) profiling. Normal renal HK-2 cells were cultured as
a monolayer in Keratinocyte Serum Free Medium (K-SFM)
supplemented with 0.05 mg/ml bovine pituitary extract (BPE),
5 ng/ml human recombinant epidermal growth factor (EGF) (Life
Technologies/Invitrogen, Carlsbad, CA, USA), 10% fetal bovine
serum (Atlanta Biologicals, Lawrenceville, GA, USA), 50 mg/ml
penicillin and 50 mg/ml streptomycin (Invitrogen, Carlsbad, CA,
USA). The renal cancer cell lines A-498 and ACHN were cultured
as a monolayer in Eagle’s Minimum Essential Medium, (UCSF
Cell Culture Facility, San Francisco, CA, USA). Caki-1 and Caki-
2 were cultured the same way in McCoy’s5A media (UCSF Cell
Culture Facility, San Francisco, CA, USA). All cell lines were
maintained in an incubator with a humidified atmosphere of 95%
air and 5% CO2 at 37uC.
Genistein Treatment of A-498 Cells
A-498 cells (60–70% confluent) were treated with genistein
(25 mM and 50 mM ). Genistein (Sigma-Aldrich Corp., St Louis,
MO, USA) was dissolved in DMSO, and cells treated with vehicle
(DMSO) served as control. Fresh genistein was administered
everyday with a change of medium, and the cells incubated for 4
days.
Quantitative Real-time PCR
For real-time polymerase chain reaction (PCR), complementary
DNA was amplified with Inventoried Gene Assay Products
containing two gene-specific primers and one TaqMan MGB
probe (6-FAM dye-labeled) using a TaqMan Universal Fast PCR
Master Mix in a 7500 Fast Real-Time PCR System (Applied
Biosystems, Foster City, CA, USA). Thermal cycling conditions
included 95uC for 20 seconds(s), 40 cycles of 95uC for 3s and 60uC
for 30s according to the TaqMan Fast Universal PCR protocol.
Total microRNA was extracted using a miRNeasy kit from
Qiagen (Valencia, CA, USA). For miRNA real-time experiments
the cDNA strand was synthesized using an Applied Biosystems
Taqman MicroRNA Reverse Transcription kit (Applied Biosys-
tems, Foster City, CA, USA), with 200 ng of total extracted
miRNA. RNU48 was used as an endogenous control. It was also
used as an endogenous control for real-time PCR experiments,
where miRNAs were isolated from formalin-fixed paraffin-
embedded (FFPE) renal samples. Total miRNA was extracted
from FFPE samples using a miRNA FFPE kit from Qiagen.
Micro Dissection of Renal Cancer Tissues and RNA
Extraction from FFPE Human Renal Tumor Samples
Adjacent normal and cancerous renal tissues were obtained
from 29 representative FFPE tissue blocks of radical nephrectomy
specimens from the Pathology Department of the Veterans Affairs
(VA) Medical Center of San Francisco. The blocks were from
kidney cancer patients who were operated on at the VA Medical
Center between 1980–2009. Sections (4 mm) of the blocks were
prepared, H&E stained, and slides were reviewed by a board
certified pathologist to mark the normal and cancer areas.
Subsequently, 12 mm slides were made from the blocks and micro
dissection was performed using the marked H&E stained slides as
a template. microRNA extraction was done using a Qiagen FFPE
miRNA extraction kit. The levels of miR-23b-3p were assessed by
the Taqman miR assay as described above. Following PCR,
relative miR-23b-3p expression levels in cancerous regions were
normalised to their adjacent normal counterparts.
Cell Transfection
A498 and Caki-2 cells were transiently transfected with either
miRNA-23b-3p inhibitor (mirVanaH miRNA inhibitor Applied
Biosystems, Assay ID no. MH10711) or anti-miR negative control
#1 (from Ambion, Austin, TX, USA Catalog no. AM17010),
using X-tremeGENE siRNA transfection reagent (Roche Diag-
nostics Indianapolis, IN, USA) according to the manufacturer’s
protocol. In brief, cells were seeded in 6 well plates (Nunc,
Roskilde, Denmark) 24 h before transfection and transiently
transfected at a confluency of 40–50%. Mock transfection, with
the transfection reagent, was also used as a control. The
transfection mixture was dissolved in Opti-MEM serum-free
media (UCSF Cell Culture Facility, San Francisco, CA, USA)
and at the time of transfection cells were seeded in Eagle’s
Minimum Essential Medium (UCSF Cell culture facility), with
10% FBS (Atlanta Biologicals, Lawrenceville, GA, USA) and no
antibiotics. On the following day the media was changed to Eagle’s
Minimum Essential Medium containing both FBS and 1%
antibiotic (penicillin–streptomycin, 100x, UCSF Cell Culture
Facility). Cells were pelleted after 72 h of transfection for flow
cytometry, RNA and protein extraction.
Cell Cycle Analysis
Cell cycle analysis was performed 72 h after transfection. The
cells were harvested, washed with cold PBS, (UCSF Cell Culture
miRNA-23b-3p in Renal Cell Carcinoma
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Facility), and resuspended in the nuclear stain 49,6-diamidino-2-
phenylindole (Beckman Coulter, Brea, CA, USA). Stained cells
were immediately analysed with a flow cytometer (Cell Lab
Quanta SC; Beckman Coulter).
Apoptosis Assay
For apoptosis, cells at 72 h after transfection were dual stained
with the viability dye 7-amino-actinomycin D(7-AAD) and
Annexin V-FITC using an Annexin V-FITC/7-amino-actinomy-
cin D kit (Beckman Coulter) according to the manufacturer’s
protocol. Stained cells were immediately analysed by flow
cytometry (Cell Lab Quanta SC; Beckman Coulter).
Migration and Invasion Assays
A cytoselect 24-well cell migration and invasion assay kit (Cell
Biolabs, Inc., San Diego, CA) was used for migration and invasion
assays at 72 hrs after transfection (8 mm, Colorimetric format)
according to the manufacturer’s protocol.
Western Analysis
Whole-cell extracts were prepared in radioimmunoprecipitation
assay buffer (RIPA; Thermo Scientific, Rockford, IL, USA;
50 mmol l–1 Tris (pH 8.0), 150 mmol l–1 NaCl, 0.5% deox-
ycholate, 0.1% SDS and 1.0% NP-40) containing a protease
inhibitor cocktail (Roche, Basel, Switzerland). Protein assays were
performed using a BCA Protein assay kit (Pierce/Thermo
Scientific, Rockford, IL, USA) according to the manufacturer’s
instructions. Total protein (40 mg) was electrophoresed in 12%
SDS–PAGE gels, and Western blotting was carried out using
standard protocols and proteins detected by chemiluminescence.
Antibodies, including PTEN (cat. no. 9552S) and Akt (cat. no.
4691S) were purchased from Cell Signaling (Danvers, MA, USA),
PI3-kinase (cat no. ab69870) and IL-32 (cat no. ab62580) were
from Abcam (Cambridge, MA, USA), whereas GAPDH (cat. no.
sc-32233) was from Santa Cruz Biotechnology (Santa Cruz, CA,
USA).
The protein expression levels were quantified by optical
densitometry using ImageJ Software version 1.36b (http://rsb.
info.nih.gov/ij/). Fold change was calculated as the ratio between
the net intensity of each sample transfected with anti-miR-23b-3p
divided by GAPDH and the negative control transfected samples
divided by the GAPDH (Anti-miR-23b-3p transfected samples/
GAPDH)/(Neg Control miR transfected samples/GAPDH).
Luciferase Reporter Assay
Cells in 24-well plates were transfected with 30 nM pre-miR
negative control (NC) or pre-miR-23b-3p (Applied Biosystems)
and PTEN construct (Catalog no. HmiT015535, Genecopoeia,
Rockville, MD, USA) or control construct, pEZX-MT01 (Gene-
copoeia) using Lipofectamine 2000 (Invitrogen), according to the
manufacturer’s instructions. The control construct lacked miR-
23b-3p target sites. All transfection experiments were performed in
triplicate. Luciferase activity was assayed at 48 h after transfection,
using a dual-luciferase reporter assay system (Promega).
Immunohistochemistry
Immunostaining was done on renal cancer tissue slides [made
from formalin-fixed, paraffin-embedded (FFPE) renal cell cancer
tissue blocks using a microtome (Leica)]. The slides were
deparaffinized and antigen retrieval was carried out by micro-
waving the slides in 10 mmol/L sodium citrate buffer. Slides were
incubated overnight with anti-PTEN antibody (Cell signalling).
The staining was done using the LABVISION Corporation
(Thermo Fisher Scientific) Anti-Rabbit Staining System (LOT-
RHD 80924) as per manufacturer’s instructions.
Statistical Analysis
Statistical analysis was performed using StatView version 5.0 for
Windows. Student’s t-test was used to compare the different
groups. p-values of ,0.05 were regarded as statistically significant.
Chi-square test was performed to determine the correlation
between miR-23b-3p expression levels and PTEN protein
expression levels in tissue samples.
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